CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Faculty Opinions recommendation of Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726145666.793525559 ◽

2016 ◽

Author(s):

Daniel Vorobiof

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00551-3 ◽

2016 ◽

Vol 17 (3) ◽

pp. 367-377 ◽

Cited By ~ 249

Author(s):

Arlene Chan ◽

Suzette Delaloge ◽

Frankie A Holmes ◽

Beverly Moy ◽

Hiroji Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30717-9 ◽

2017 ◽

Vol 18 (12) ◽

pp. 1688-1700 ◽

Cited By ~ 212

Author(s):

Miguel Martin ◽

Frankie A Holmes ◽

Bent Ejlertsen ◽

Suzette Delaloge ◽

Beverly Moy ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969433.793480577 ◽

2013 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Her2 Positive ◽

Phase 3 ◽

Randomised Controlled ◽

Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06166-y ◽

2021 ◽

Author(s):

Chiun-Sheng Huang ◽

Youngsen Yang ◽

Ava Kwong ◽

Shin-Cheh Chen ◽

Ling-Ming Tseng ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapy ◽

Neoadjuvant Chemotherapy ◽

Invasive Disease ◽

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 3 ◽

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30570-9 ◽

2018 ◽

Vol 19 (12) ◽

pp. 1630-1640 ◽

Cited By ~ 34

Author(s):

Mette S van Ramshorst ◽

Anna van der Voort ◽

Erik D van Werkhoven ◽

Ingrid A Mandjes ◽

Inge Kemper ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial

Cancer ◽

10.1002/cncr.32653 ◽

2019 ◽

Vol 126 (6) ◽

pp. 1175-1182

Author(s):

Antroula Papakonstantinou ◽

Alexios Matikas ◽

Nils Olof Bengtsson ◽

Per Malmström ◽

Elham Hedayati ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Efficacy And Safety ◽

Her2 Positive ◽

Phase 3 ◽

Dose Dense ◽

Faculty Opinions recommendation of Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718178616.793487310 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Neoadjuvant Treatment ◽

Her2 Positive ◽

Phase 3 ◽

Randomised Controlled ◽

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30716-7 ◽

2018 ◽

Vol 19 (1) ◽

pp. 115-126 ◽

Cited By ~ 101

Author(s):

Sara A Hurvitz ◽

Miguel Martin ◽

W Fraser Symmans ◽

Kyung Hae Jung ◽

Chiun-Sheng Huang ◽

...

Keyword(s):

Breast Cancer ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

BioDrugs ◽

10.1007/s40259-021-00475-w ◽

2021 ◽

Author(s):

Binghe Xu ◽

◽

Qingyuan Zhang ◽

Tao Sun ◽

Wei Li ◽

...

Keyword(s):

Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Equivalence Trial ◽